Identification and Validation of Epigenetic Biomarkers of PMDD (BIO)

Johns Hopkins University

Status: Begins enrollment this month

Conditions: Premenstrual Dysphoric Disorder (PMDD); Menstrual Cycle; Premenstrual Syndrome; Premenstrual Syndrome-PMS; PMDD

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT06771583

1R01MH135896 (U.S. NIH Grant/Contract)

IRB00484410

Details and patient eligibility

About

This research is being done to examine epigenetic markers and mood changes across the menstrual cycle, particularly in premenstrual dysphoric disorder (PMDD). The investigators previously identified epigenetic biomarkers of postpartum depression, another reproductive affective disorder, and in this study aim to determine if these biomarkers also distinguish PMDD cases from healthy controls at different points in the menstrual cycle. By collecting biological samples (such as blood) and monitoring mood changes across the menstrual cycle, the investigators will be able to determine whether these epigenetic markers are associated with PMDD. The investigators plan to study these epigenetic markers during the follicular phase (roughly the first half of the menstrual cycle, from menses until ovulation) and the luteal phase (roughly the second half of the menstrual cycle, from ovulation to menses). The investigators will study this in two groups: 1) individuals who do NOT have premenstrual mood symptoms, and 2) individuals with premenstrual syndrome/premenstrual dysphoric disorder (PMS/PMDD). The results will provide a comprehensive view of the changes in these systems across the menstrual cycle. This will add to the investigators understanding of the mechanisms that may cause PMS/PMDD.

Full description

Premenstrual dysphoric disorder (PMDD) is a reproductive affective disorder with impairing mood symptoms that emerge monthly in the premenstrual (luteal) phase of the menstrual cycle. Reproductive affective disorders, including PMDD and postpartum depression, can be conceptualized as disorders of hormone sensitivity - an abnormal brain response to ovarian hormone fluctuations. Epigenetic variations in prior studies by the investigators were prospectively predictive of postpartum depression risk with over 80% accuracy. Recently, in a cross-sectional cohort of 50 women with and without PMDD, this postpartum depression epigenetic biomarker distinguished PMDD cases from controls in the luteal phase, suggesting this may indicate sensitivity to reproductive hormone change. The primary aim of this study is to explore whether this epigenetic biomarker is a broad marker for hormone sensitivity, by assessing women (controls, PMDD) in both the follicular and luteal phases of the participant's menstrual cycles, using a repeated measures approach. A secondary aim is to examine whether the epigenetic biomarkers differ between women with PMDD who have responded to selective serotonin reuptake inhibitor (SSRI) treatment versus those who have failed SSRIs. SSRIs are the first-line treatment for PMDD, yet many PMDD patients do not respond to SSRIs. This study will assess DNA methylation in a cohort of women with PMDD and controls. The investigators will compare the epigenetic biomarker between controls and PMDD in the follicular and luteal phases. Within the PMDD group, the investigators will compare the biomarker between those who have responded to SSRI treatment and those who have not. Blood will be collected at home by participants using a dried blood spot collection system.

Enrollment: 500 estimated patients

Sex: Female

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• female sex
• regular menstrual cycles (24-35 days)
• age 18-50 years
• ability to give written informed consent

Exclusion criteria

• psychiatric medication use in the past 2 months;
• substance use disorder in the past 2 months (per MINI);
• lifetime history of psychotic disorder including schizophrenia, schizoaffective disorder, major depression with psychotic features (per MINI);
• history of psychiatric disorder other than PMDD in past year (per MINI);
• active suicidal ideation with plan or attempt in past 6 months (per MINI);
• steroid hormone or hormonal contraceptive use (except levonorgestrel as emergency contraceptive) in past 2 months;
• pregnancy in past 6 months;
• history of brain injury;
• current or history of endocrine disorder including uncontrolled diabetes or thyroid disease;
• BMI>40.

Trial design

500 participants in 2 patient groups

Control

Description:

Eligible participants that pass inclusion and exclusion criteria who do not have premenstrual mood symptoms.

Premenstrual Dysphoric Disorder (PMDD)

Description:

Eligible participants that pass inclusion and exclusion criteria who do have premenstrual mood symptoms. Symptoms must be severe enough to meet PMDD criteria.